Are Advances in Medicine Helping Us?
It is an undeniable fact that throughout time the invention of new technology and
the advancement of scientific knowledge have helped to advance the medical world. If
one was to look at any period of time it can be seen that advances in science and
technology allow the ability to provide healthcare to also advance. Yet, as our ability to
use new technology becomes greater and greater, the question of the detrimental effects
of such progress begins to appear. It is clear that many of these new additions to our
knowledge provide a greater ability to treat the sick, to prolong life, and to allow medical
crises to be averted. However, in some instances, these new technologies seem to hurt
more than they help. As technology continues to increase, and new medications and
technologies become important in the medical field, the relationship between increasing
technology and the medical field will continue to become a major issue and because of
this is an important issue to be faced by our generation.
For anyone who enters a location of medicine in today’s world, it is clear that
without technology and scientific discoveries, nothing would work as it does. Every
aspect of the modern medical system requires these features. It is also apparent, not only
from looking at today but also into the past, that as new technologies appear, they make a
great impact on the medical world. This can be seen at the beginning of the twentieth
century. At this time great advancements were made in sciences including chemistry,
physiology, pharmacology, etc. Such advances allowed great strides in medical
discoveries. One of these discoveries, which could be said to have had the greatest
impact, was the development of the x-ray. By the 1930’s “The power this technological
innovation gave physicians was enormous. The x-ray permitted them to diagnose a wide
variety of diseases and injuries accurately” (Blanchard, 10). Such advancement was very
important for the medical field as it allowed diagnosis to be a great deal more accurate.
As new medications were introduced, the hospital and treatments of patients begin to
transform toward the modern day. Through such consideration of the past, it is clear that
advances in science and new discoveries have and will continue to cause great changes in
the medical world. It is clear that such positive effects are still occurring today and that
new pieces of knowledge add tremendously to our healthcare system. However, in
today’s world, one begins to question if all these advancements are actually as positive as
The new methods of treatment which have become possible through today’s
expanding technology bring about not only positive effects but also some which can be
harmful. With the ability to use new technologies and medications, comes the question
of whether they should actually be used. Because of this, a variety of questions come
into debate. As medical technology rapidly advances, “capabilities have also produced
great uncertainty as to what is most beneficial or least harmful for the patient”
(Blanchard, 41). A key point in the medical field is to do what is considered to be most
beneficial to the patient and above all to do no harm. The uncertainty of what will be the
most beneficial for the patient causes a judgment to be made by those giving treatment.
The fact that technologies are used before there is knowledge they will actually be of
benefit to those treated also causes one to wonder if the system in place is actually sound.
The United States has an obsession with using the newest technology. However, this
obsession brings an inquiry of if this is actually the best idea. Unlike new medications,
new technologies must not be proven to have a positive effect before they are put into
use. And due to the nature of the American medical system, these new machines, which
have not been extensively studied to show their benefit, are used to a high degree.
Although it is clear many of these changes are beneficial, some such as artificial spinal
disks have not been shown to make any changes, while others have actually been shown
to be detrimental. “Physicians were stunned, for example, when clinical trials showed
last year that expensive anemia medicines might actually hasten death in kidney and
cancer patients” (Berenson). As we move into the future it is clear that more and more
new technologies will continue to be introduced, if there is the possibility of each having
detrimental effects, it seems as though the system needs to be changed. There have been
too many times when it was thought these technologies would do one thing but instead
did another, it is evident that studies should be required before such technologies are
Further, it is apparent that this same fascination which the American people have
with the newest medical technology may be having detrimental effects financially.
“Some medical experts say the American devotion to the newest, most expensive
technology is an important reason that the United States spends much more on health care
than other industrialized nations — more than $2.2 trillion in 2007, an estimated $7,500 a
person, about twice the average in other countries — without providing better care”
(Berenson). The use of new technology is important and can be of great benefit to the
country; however, it is clear that the way in which it has been used is not of great benefit.
Because it is not often known if the technologies will be of benefit to the patient, it is
generally left to the physician to decide when and how they should be used. This leaves
them with a dilemma of trying to decide if it will be of benefit, often without much proof
either way. This can be seen in the example of the CT heart scan. This machine allows
for a better view than previously possible inside the heart, however, it also exposes the
patient to radiation. Many of those who have purchased the scanner are using it to a high
degree, and according to some doctors, they are over using it, exposing patients who do
not need the scanner to radiation when it is not necessary. In many cases, patients who
have shown no symptoms of heart disease have still been scanned, although in some
instances this has in fact shown they needed some kind of lifestyle change or a stent put
in, in many cases no issues were found. This implies a needless exposure to radiation and
an elevated risk of cancer. Such an example brings into question whether these
technologies are benefitting the patients in all cases, and if they are not, it makes the
It is clear that there are some financial incentives to use such technologies. Once
the FDA has approved a new device, it is rare that companies such as Medicare will not
cover them. In some instances, such as the example of the CT heart scan, it is clear that
when they did not feel they should cover the technology without studies done, they were
met with great resistance. “Concerned about the overall proliferation of imaging tests,
Medicare said it might require a large-scale study to determine the scans’ value. The plan
met with fierce resistance…” (Berenson). Those promoting coverage have claimed that
breakthrough technologies need time to prove themselves. Although this can be seen to
be true, it also brings into question how many detrimental effects will occur during this
time. Medicare eventually dropped pushing such efforts and no studies have been forced
to occur. Such an example makes it clear that it is very rare that these new machines will
not be covered by insurance due to the push of those promoting it, and so, they can easily
be put into use. Further, when doctors use such medications on patients, they charge a
substantial fee. Although these machines are expensive to buy in the first place, they
more than make up for their costs. A considerable amount of the income of many
doctors, especially those within fields of specialty, comes from the use of such new
technologies. Because they realize they will make such a profit, it seems quite possible
that many of these doctors could overuse new technologies. This use can clearly provide
benefits to the patients, the question remains however if the risk and the cost outweigh
the benefits and if this technology is truly being used as it should.
As technology continues to grow, new discoveries in the uses of medications are
also occurring. Because of this, medication is being prescribed much more often than in
the past and is often being taken in ways it shouldn’t be. This has caused diseases to
mutate and become resistant to drugs. People and animals are on preventative
medications, and medications are at times prescribed incorrectly causing detrimental
effects upon the patient. As doctors prescribe antibiotics much more commonly than ever
before, and people begin to take more and more preventative medications, diseases begin
to change. Antibiotic resistance became increasingly common between 1987 and 1994,
possibly due to the overuse of the antibiotics prescribed. These drug resistant bacteria
had mutated slightly so that penicillin could not break down their cell walls and so the
cells could not be harmed, leaving the illness untreatable by the current antibiotics. At
this time drug companies thought that no more antibiotics were needed and they had
solved this issue, and instead were trying to find other types of medications. This lead to
no medications being available for these drug resistant diseases, leading to the deaths of
many people (Lewis). Issues such as the overuse of broad-spectrum antibiotics, incorrect
diagnosis, unnecessary prescriptions, and improper use of antibiotics by patients have
been shown to lead to such mutations which cause antibiotic resistance. It is also thought
that the use of antibiotics in livestock used to promote growth and to prevent the
possibility of disease may also lead to this resistance. Such types of resistance lead to a
The emergence of drug resistance in several diseases, including tuberculosis,
HIV/AIDS, malaria, and bacterial infections, began to be recognized as a global threat in
the 1990s. In most first world countries, this drug resistance is thought to be caused by
the treatment of animals with antibiotics (most feed animals are given prophylactic
antibiotics which are often unsystematically applied) as well as failing to complete a
course of antibiotics, or the over prescription of antibiotics. In other parts of the world it
is thought that drug resistance is also caused by unreliable access to drugs paired with
incomplete courses, as well as switching between antibiotics over the course of a
treatment (Lewis). There are two types of drug-resistant tuberculosis, multi-drug
resistant tuberculosis (MDR TB) and extremely drug resistant tuberculosis (XDR TB).
As the name of each implies, the multi-drug resistant strain is resistant to some generally
used TB medications and the extremely drug resistant strain is resist to most of the drugs.
Extremely drug resistant TB is often found to be untreatable. “The chronic features of
tuberculosis in these patients suggest that extensively drug-resistant tuberculosis may be
acquired through previous treatments that include second-line drugs” (Keshavjee). It is
necessary to treat this disease aggressively in order to help prevent the spread of it as well
as to prevent fatality. Multi-drug resistant tuberculosis is also said to occur “when
patients do not complete their full course of treatment, when health-care providers
prescribe the wrong treatment, the wrong dose, or length of time for taking the drugs,
when the supply of drugs is not always available, or when the drugs are of poor quality”
(cdc.gov). In looking at this disease, the way in which it is transferred must also be
considered. Tuberculosis is very contagious and can be spread by breathing in air
droplets of the cough or sneeze of an infected person. Because of this, those who have
this disease could easily infect anyone with whom they come into contact. “There was
one study that found that a single TB patient can infect 14 other people in the course of a
single bus ride.” (Kristof). This emphasizes the point that those carrying this disease
pose a major risk even to those who might be in the same room or bus as them. Yet,
these people are generally not isolated in any way, but do use public transportation and
are able to infect others, without meaning to or knowing they have. Tuberculosis is not
often thought about as a major issue by most people in the United States; however, this is
something which should put into our consideration. HIV/AIDS was once also not
considered something which was going to be a major issue for our country and it has
become clear that this was a mistake. Drug-resistant TB is spreading, in a world
connected by planes and constant flows of immigrants and tourists. As the world
continues to become increasingly connected, we need to consider this issue. If nothing is
done, and it continues to be ignored and allowed to spread at its current rate, we run the
risk of having our shortsightedness catch up with us, just as it did with HIV and AIDS.
Issues such as those highlighted by these two strains of tuberculosis are also a
major issue with other drug resistant diseases. As time goes on and people continue to
incorrectly treat diseases, self-medicate and over medicate, and ignore the instructions of
doctors the issue of drug resistance will continue to spread. This will spread not only due
to people spreading to one another, but also due to people having mutations of diseases
within their bodies. This is an issue which will need to be considered and resolved in
order to prevent such an occurrence. This requires both cooperation from the patient and
the healthcare provider. The patient needs to work with the healthcare provider to follow
instructions and the healthcare provider needs to correctly diagnose and treat the disease
as well as to make sure the patient is completing their treatment. This also means the
patient must be able to both access and afford to complete their medications, which is
Not only can financial incentives be seen in order to use new technologies but
also in the cost of medications. This can be seen by the drug companies as well as by
pharmacies. It is clear that drug companies make a large profit on the medications which
they produce. It is also evident that when generic versions of their medications become
available many people will switch to the generic version in order to save money.
Because of this, companies such as that making Lipitor have tried to allow their
exclusivity to last as long as possible. It is clear in these situations that they are not
concerned about allowing the cost for the patient to be less but instead in their own
profits. Lipitor is a cholesterol medication and is the world’s top drug, with $12.7 billion
in sales last year. This medication is taken by a large amount of people in the world and
is clearly important to the health of these people. “Lipitor’s current price can exceed $3 a
day, while a generic version might eventually sell for well below $1” (Saul). This would
make a great difference for the vast number of people on this medication. However, an
agreement has been made with the company which has made a generic version of the
medication to delay its release. This delay will last up to twenty months, until November
2011, making a huge impact on those using this medication. During these months, it is
projected that Lipitor will add billions to their profits. Such an agreement can clearly be
seen to have financial incentives and is not considering the good of the people. It is also
clearly an obstacle for those who find it difficult to afford their medications.
When one looks at the amount of money charged at pharmacies such as CVS and
Walgreens, it is quite evident that the cost is much higher than is actually necessary for
many medications, especially that of generic drugs. Such an issue is often not felt by
those who have insurance as it is those companies which will pay for most of the cost of
the medication, and these companies are given deals because of the large quantities which
they by. However, those who do not have insurance will feel great effects. Often,
unfortunately, it is these people who are at the highest risk of not being able to afford
these high costs. This can cause people to take their medications incorrectly which in the
end can cause major issues. Because of this it has been seen that some people will take
less medication daily in order to make it last longer, stop treatment before they should, or
switch medications at a point they should not in order to lower the cost. These choices
can often be seen to be detrimental to the health of the patient.
If one looks at the cost of the generic version of the drug Zocor, a medication
taken to help lower cholesterol, the ridiculously high cost of medication, which is
seemingly unnecessary, is clearly illustrated. This medication’s patent expired in June
2006 allowing for generic versions to be available. This introduction of generic versions
would seemingly imply that a great decrease in price; however, in most instances this is
not the case. “At online pharmacy walgreens.com, for instance, the price for 30 tablets of
a 20-milligram dose of Merck & Co.'s Zocor is $149.99, compared with $89.99 for
simvastatin, the generic version. And last week, the same dose of simvastatin cost
$108.99 at CVS's Web site, compared with $154.99 for Zocor.” (Rubenstein). It is clear
that the expected lowering of cost did not occur, but instead only a slight drop in price.
However, at other pharmacies such as Sam’s Club and Costco, the prices of these same
generic medications are vastly different. “Simvastatin costs $6.97 for 30 pills of the 20-
milligram dose at a Sam's Club for which the company provided price information.”
(Rubenstein). This is clearly an immensely different price from the prices seen at CVS
and Walgreens, yet, it is for the same product. Sam’s Club says that they are still making
a profit on these medications meaning that these pharmacies are choosing to charge a
much higher price than is really necessary. However, these companies claim that they
need to charge such high prices. It seems ridiculous that such a difference can exist, and
unfortunately it is often the case that people do not act upon these price differences but
continue to go to the pharmacy they are used to (which in most cases is charging the
higher prices). It is clear that changes need to occur in order to allow for a system which
better aids those who are attempting to receive medical care instead of simply being for
the economic benefit of those who are supplying the care.
There are important gaps which are clearly apparent in the health care system and
if they are not repaired, this will continue to become an increasingly large issue. Because
of this, I feel that my generation is going to have to reform the system and this will be a
major issue we will face. There is a major gap between the US spending on healthcare
and the results which are achieved. Second, there is a major gap between the use of new
technologies and the proof that these technologies will be of benefit. Third, there is a gap
between the risk due to diseases and the education and treatment necessary in order to
prevent them. Finally, there is a gap between the cost to the public for treatment and the
cost to the companies providing the treatment. If these gaps are not narrowed and these
problems are not fixed, there will be major issues. If we are not able to deal with these
issues, diseases will not be able to be treated and will continue to spread. The life
expectancy could easily begin to lower as people begin to become sicker and sicker and
not have possibility of treatment, not only due to drug resistance but due to the cost of
medical care which continues to rise. If people are unable to be healthy, they will
certainly not be able to deal with other areas of life and we will see major issues in many
places. These increasingly sick people will not be able to go to school or work, they will
not be able to learn or add to our economy, we will slowly deteriorate as a people. Such
ideas seem to be completely ridiculous; however, if we continue to disregard issues
which need to be addressed, these issues are clearly possible.
The first gap, that between US spending and the results it has achieved is very
clear. The United States is spending more on healthcare than any other country and yet it
is not finding itself to actually be achieving results proportional to this spending. It is
clear that a major reason for this is the excessive use of technology in the American
healthcare system. It is clear that unnecessary spending is occurring; yet the actual
amount of unnecessary spending remains unknown. However, one study estimated that
one-third or more of the care that patients in this country receive could be of little value.
(Berenson). It is clear that this is not an acceptable standard for the country and that
something needs to be done in order to have our spending allow all patients to receive
care which will be of benefit to them. It is clear that the unnecessary spending needs to
be discontinued, however, we must first analyze where and when such spending occurs.
It is clear that some of this spending is due to the over use of technology and this issue
should clearly be worked on. If we close the gap between the evidence something will
work and its use, it is clear that some technologies will no longer be used or they will not
be used in the situations in which they are. However, it is unlikely that making such
regulations will take care of this entire issue. It is also necessary to then find a way to
provide care to everyone. By not making sure everyone receives the care they need, not
only are those people being hurt, but the society as a whole. As people continue to get
sick, they are able to spread their illness, which allows for more and more people, many
of which likely will not get the care needed to be ill. Such a cycle needs to discontinue
and in order to do this we must narrow and eventually close this gap.
The second gap, between technologies and their proof, clearly plays a role in the
first as it has been seen to have a great impact on spending. However, this is not the only
reason this gap must no longer exist. It is evident that some technologies are actually not
doing what they were expected to do and are detrimental to the patients. Although this is
not necessarily a common occurrence, such an issue should never be allowed to occur
outside of a trial setting. Because of this, it is necessary to begin having regulations for
technologies just as we do for new medications. Although this may mean the cutting
edge technologies take longer to be released, its impacts will be better for the system. By
allowing these technologies to be tested, doctors will know when they should and should
not use a technology. This will lead to less overuse of technology as there will now be
guidelines for use. This can allow for rules and regulations about the use of these
technologies which will also help to solve the issue of overuse. Finally, this will allow
less technologies to actually be released meaning there will be less spending on
technologies and only those which are truly helpful will be used. It is clear that these
changes would be beneficial not only economically but also to the health of the patients
as those new technologies which would be detrimental or would simply not be justified
because the results do not seem to be any better than older cheaper methods would no
The third gap, between the danger of diseases and the public understanding of this
danger as well as the efforts to treat these diseases is another major issue. It is clear in
many cases that the public as a whole does not have a true understanding of the danger of
many diseases which are apparent in today’s world. Although the general public cannot
be expected to know about every disease which may be encountered, it is important for
them to have an understanding of what is generally around them. Those who are
suffering from a disease, especially those which are drug resistant, need to be informed of
the consequences of their disease, how they could spread it, and what they should do to
prevent this. This type of education will be helpful in order to help people to avoid such
diseases and prevent spreading which does not need to occur. Causes of drug resistant
bacteria could often be prevented if we make efforts to educate people to stop this from
occurring, and it is this type of education which is necessary. In order to close this gap
the medical community needs to make great efforts not only to educate but also to work
to find ways to stop spreading. It is obvious that diseases which are extremely
contagious, such as resistant forms of tuberculosis, need to be prevented from spreading.
However, it is clear that currently, this is not being stopped. People with these diseases
are clearly able to travel on public transportation in which they could spread the disease.
It is also obvious that it would be wrong to tell these people they cannot have lives as
they did not chose to get sick, however, something must be done in order to prevent
others from being given the illness. Such a problem is difficult to solve and an easy
answer does not seem apparent, however, it is clear that something must be done in order
to prevent this spread. Education would clearly be a step in the right direction, however
it is also clear that education will not be enough to fully solve this problem and because
of this more steps will have to be taken in order to close this gap.
The final gap, that of cost to the patient vs. cost to companies is another major
issue which can be seen to be faced in today’s world. If this gap is allowed to continue to
exist, it is clear that people will continue to not take medication or take it in a way that
they shouldn’t. If people are unable to afford their medications as they are meant to take
them, they are going to try to find ways to solve this problem, unfortunately in many
cases people’s solutions are doing more harm than good. It is quite evident that the
companies who are making the medications and the pharmacies that are selling them, in
most cases, are making a huge profit. They are clearly not considering the patient but
considering their own wish for economic advantages. It is also quite obvious that if this
gap is not narrowed, the issues which are currently occurring will continue to and
because of this, something must be done. Companies such as Sam’s Club and Costco are
clearly offering a more affordable situation, however, this is not so well advertised as to
allow all of the general public to know the price difference. It is likely that more
advertisement would allow these price differences to be of some help in this situation.
Walmart is also offering cheaper prices for generic medications; this program is well
advertised and is likely to be used by those who need cheaper prices. Such companies
are clearly helping with the issue at hand, however, it is clear that this is not enough and
more changes need to be made to solve this problem. Unfortunately, this is an issue
which is mainly one of greed. It is unlikely that companies will decide to lower their
prices just to be nice to those who currently can’t afford medications. However, it is
possible for the government to pass laws in order to force lower prices. It is not
justifiable for these people to continue to make billions of dollars each year in profits
while the people who really need the medications are not able to afford them. Such a law
should not cause a lack of profits, however, it should allow for the prices to be lowered,
possibly lowering the profits of the drug companies by a small amount, though not so
drastically as to be truly detrimental to those working there. This solution is not the
simplest choice, and clearly would be met with a great amount of resistance. However, it
is clear that such a solution would be of great benefit to many people.
The gaps which are apparent in the current healthcare system have the potential
for creating major problems in the world as we move into the future. However, if people
work to eliminate these gaps, these problems will not occur. Although it is obvious
closing the four gaps mentioned will not be an easy nor is it a quick task, every step made
to try to solve these problems is one step closer to a better healthcare system. This work
requires the efforts not only of the healthcare providers but also of the government and of
the general public. Through the efforts of the community as a whole, we will be able to
solve such problems and change a future of devastation to one of hope. If everyone is
willing to work together to solve these problems, I feel there is potential for great
improvement and the possibility of great advances for the future of the medical world.
Berenson, Alex, and Reed Abelson. "The Evidence Gap: Weighing the Costs of a CT
Scan’s Look Inside the Heart." New York Times 29 June 2008.
Blanchard, Susan M., John D. Enderle, and Joseph D. Bronzino. Introduction to
Biomedical Engineering. New York: Academic P, 2005.
"DTBE Fact Sheet Multidrug-Resistant Tuberculosis." Fact Sheet. 16 Oct. 2008. CDC. 5
Dec. 2008 <http://www.cdc.gov/tb/pubs/tbfactsheets/mdrtb.htm>.
Kristof, Nicholas D. "A Killer Without Borders." New York Times 6 Dec. 2008. Lewis, Ricky. "The Rise of Antibiotic-Resistant Infections." FDA Consumer Magazine
Rubenstein, Sarah. "Why Generic Doesn't Always Mean Cheap Zocor Case Shows
Drugstores May Offer Only Small Savings Over Brand-Name Drug Prices." Wall Street Journal 13 Mar. 2007.
Saul, Stephanie. "Release of Generic Lipitor Is Delayed." New York Times 19 June
e x c e l l e n c e y o u c a n t r u s tAPPLICATION FORM MedICINe RISK MANAGeMeNTI authorise my medical practitioner to furnish and/or disclose to the Medicine Management Programme any fact relating to this application as well as any additional information that may be required from time to time. (Remember that your medical practitioner bears the responsibility of prescribing the medication for
Principal Investigator/Program Director (Last, first, middle): Llovet, Josep M. BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FOUR PAGES. Professor of Research, University of Barcelona. JLLOVET EDUCATION/TRAINING (Begin with baccalaureate or other initial professional e